Drotrecogin alfa activated
ApprovedSmall molecule
Eli LillyDrotrecogin alfa activated is one of 137 small molecule programs targeting Sepsis. It is currently in Approved.
4
Indications
13
Total Trials
0
Active Trials
136
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Drotrecogin alfa activated
Eli LillyApproved
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Levaquin
WWim Janssens
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Pitocin
RRetrophin
Preclinical
Nacl
BayerPreclinical
Thymosin Alpha 1
SSun Yat-sen University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sepsis6 trials
Septic Shock2 trials
Effectiveness1 trial
Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness
Completed·—··NCT02843685·12,492 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Drotrecogin alfa activated. EMBL-EBI & Wellcome Sanger Institute.
- [4]